NCT01821846View on ClinicalTrials.gov

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

CompletedOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

November 20, 2013

Primary Completion Date

March 8, 2017

Study Completion Date

March 8, 2017

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).

Trial Locations (7)

44455

Novo Nordisk Investigational Site, Ulsan

431-796

Novo Nordisk Investigational Site, Pyungchon-Dong 896, Dongan-Gu

02447

Novo Nordisk Investigational Site, Seoul

03080

Novo Nordisk Investigational Site, Seoul

150-950

Novo Nordisk Investigational Site, Seoul

682-060

Novo Nordisk Investigational Site, Ulsan

220-701

Novo Nordisk Investigational Site, Wŏnju

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01821846 - Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter